Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SUM149PT | TNBC | Basal B | Afatinib | EGFR/HER2 | ErbB | 0.000171 | uM | 11937.158 | 0.9811 | 0.9830 | 2.2386 | |
| SUM149PT | TNBC | Basal B | Afatinib | EGFR/HER2 | ErbB | 0.000853 | uM | 11937.158 | 0.9143 | 0.9216 | 2.2386 | |
| SUM149PT | TNBC | Basal B | Afatinib | EGFR/HER2 | ErbB | 0.00427 | uM | 11937.158 | 0.9196 | 0.9265 | 2.2386 | |
| SUM149PT | TNBC | Basal B | Afatinib | EGFR/HER2 | ErbB | 0.0213 | uM | 11937.158 | 0.7153 | 0.7220 | 2.2386 | |
| SUM149PT | TNBC | Basal B | Afatinib | EGFR/HER2 | ErbB | 0.107 | uM | 11937.158 | 0.4428 | 0.3899 | 2.2386 | |
| SUM149PT | TNBC | Basal B | Afatinib | EGFR/HER2 | ErbB | 0.533 | uM | 11937.158 | 0.4464 | 0.3949 | 2.2386 | |
| SUM149PT | TNBC | Basal B | Afatinib | EGFR/HER2 | ErbB | 2.67 | uM | 11937.158 | 0.2952 | 0.1596 | 2.2386 | |
| SUM149PT | TNBC | Basal B | Afatinib | EGFR/HER2 | ErbB | 13.3 | uM | 11937.158 | 0.0165 | -0.6806 | 2.2386 | |
| SUM149PT | TNBC | Basal B | Afatinib | EGFR/HER2 | ErbB | 66.7 | uM | 11937.158 | 0.0042 | -0.8261 | 2.2386 | |
| SUM159PT | TNBC | Basal B | Afatinib | EGFR/HER2 | ErbB | 0.000171 | uM | 11057.158 | 1.0095 | 1.0049 | 3.8594 | |
| SUM159PT | TNBC | Basal B | Afatinib | EGFR/HER2 | ErbB | 0.000853 | uM | 11057.158 | 1.0236 | 1.0121 | 3.8594 | |
| SUM159PT | TNBC | Basal B | Afatinib | EGFR/HER2 | ErbB | 0.00427 | uM | 11057.158 | 0.9861 | 0.9927 | 3.8594 | |
| SUM159PT | TNBC | Basal B | Afatinib | EGFR/HER2 | ErbB | 0.0213 | uM | 11057.158 | 0.9375 | 0.9668 | 3.8594 | |
| SUM159PT | TNBC | Basal B | Afatinib | EGFR/HER2 | ErbB | 0.107 | uM | 11057.158 | 0.8550 | 0.9205 | 3.8594 | |
| SUM159PT | TNBC | Basal B | Afatinib | EGFR/HER2 | ErbB | 0.533 | uM | 11057.158 | 0.8924 | 0.9419 | 3.8594 | |
| SUM159PT | TNBC | Basal B | Afatinib | EGFR/HER2 | ErbB | 2.67 | uM | 11057.158 | 0.5310 | 0.6975 | 3.8594 | |
| SUM159PT | TNBC | Basal B | Afatinib | EGFR/HER2 | ErbB | 13.3 | uM | 11057.158 | 0.0174 | -0.3001 | 3.8594 | |
| SUM159PT | TNBC | Basal B | Afatinib | EGFR/HER2 | ErbB | 66.7 | uM | 11057.158 | 0.0004 | -0.7343 | 3.8594 | |
| SUM185PE | TNBC | Luminal | Afatinib | EGFR/HER2 | ErbB | 0.000171 | uM | 12269.165 | 1.4026 | 2.5147 | 0.6001 | |
| SUM185PE | TNBC | Luminal | Afatinib | EGFR/HER2 | ErbB | 0.000853 | uM | 12269.165 | 0.9780 | 0.9272 | 0.6001 | |
| SUM185PE | TNBC | Luminal | Afatinib | EGFR/HER2 | ErbB | 0.00427 | uM | 12269.165 | 1.4625 | 2.7683 | 0.6001 | |
| SUM185PE | TNBC | Luminal | Afatinib | EGFR/HER2 | ErbB | 0.0213 | uM | 12269.165 | 1.2840 | 2.0335 | 0.6001 | |
| SUM185PE | TNBC | Luminal | Afatinib | EGFR/HER2 | ErbB | 0.107 | uM | 12269.165 | 1.4070 | 2.5333 | 0.6001 | |
| SUM185PE | TNBC | Luminal | Afatinib | EGFR/HER2 | ErbB | 0.533 | uM | 12269.165 | 1.4007 | 2.5068 | 0.6001 | |
| SUM185PE | TNBC | Luminal | Afatinib | EGFR/HER2 | ErbB | 2.67 | uM | 12269.165 | 1.1776 | 1.6262 | 0.6001 |